Diet and quality of life during ovarian cancer maintenance therapy
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at how eating habits may affect the outlook for people with ovarian cancer who are taking a maintenance drug called a PARP inhibitor. By understanding your diet, researchers hope to find ways to improve treatment results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have been diagnosed with high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- You have had surgery and platinum-based chemotherapy as your first treatment, and your cancer responded well (complete or partial response).
- You are currently taking a PARP inhibitor for the first time as maintenance therapy after finishing first-line treatment.
- You can remember and report what you usually eat, and you are willing to fill out a food questionnaire.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a supervised exercise and nutrition program can improve well-being for people with ovarian cancer who are taking a maintenance drug called a PARP inhibitor after finishing their first round of chemotherapy. Participation may help manage side effects and support overall health.
This study asks people with advanced ovarian cancer about their preferences for treatment with PARP inhibitors (a type of maintenance therapy). The goal is to learn what matters most to patients for their quality of life.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
This trial studies how well older adults (70+) with advanced ovarian cancer tolerate PARP inhibitors in real-world care. It aims to see if the standard dose works for this age group.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.